Apnimed, Inc. Debt Conversion, Converted Instrument, Rate
Apnimed, Inc. (APMD) had Debt Conversion, Converted Instrument, Rate of 10.00% as of 2025-09-30, per its 10-Q filed 2026-09-08.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentRate · last filed 2026-09-08
- 2025-09-30: Debt Conversion, Converted Instrument, Rate 10.00%.
| Period end | Debt Conversion, Converted Instrument, Rate |
|---|---|
| 2025-09-30 | 10.00% 10-Q · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B |